No headlines found.
Protalix BioTherapeutics Letter to Stockholders
PRNewswire (Mon, 5-Jan 6:50 AM ET)
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement
PRNewswire (Wed, 17-Dec 6:50 AM ET)
Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results
PRNewswire (Thu, 13-Nov 6:50 AM ET)
PRNewswire (Thu, 6-Nov 6:50 AM ET)
Globe Newswire (Wed, 5-Nov 10:50 AM ET)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
Protalix Biotherapeutics (De) trades on the AMEX stock market under the symbol PLX.
As of January 29, 2026, PLX stock price climbed to $2.07 with 705,567 million shares trading.
PLX has a beta of 1.30, meaning it tends to be more sensitive to market movements. PLX has a correlation of 0.07 to the broad based SPY ETF.
PLX has a market cap of $166.47 million. This is considered a Micro Cap stock.
Last quarter Protalix Biotherapeutics (De) reported $18 million in Revenue and $.03 earnings per share. This fell short of revenue expectation by $-194,300 and missed earnings estimates by -$.02.
In the last 3 years, PLX traded as high as $3.55 and as low as $.82.
The top ETF exchange traded funds that PLX belongs to (by Net Assets): IWM, IWO, VTWO, IWC, EES.
PLX has underperformed the market in the last year with a price return of -10.4% while the SPY ETF gained +16.0%. PLX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -10.0% and +0.5%, respectively, while the SPY returned +1.3% and +0.5%, respectively.
PLX support price is $1.99 and resistance is $2.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PLX shares will trade within this expected range on the day.
